Short-term Effect of Intensive Insulin Therapy on Incretin Secretion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-10-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In type 2 diabetic patients, abnormality in secretion or action of incretin(GLP-1, GIP) is observed. Although controversy still exists, the secretion of GLP-1 is thought to be reduced by 20-30% while GIP secretion is normal or slightly elevated, in type 2 diabetic patients. Various parameters such as the duration of diabetes, the amount of meal and their constitution, gastric bypass surgery, and some antidiabetic drugs affect the secretion of incretin. However, the secretion of GLP-1 and GIP in glucotoxic condition and whether they recover after improvement of glycemic status is not known. The investigators aim to study the effect of intensive insulin treatment in uncontrolled diabetic patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Short-term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes Patients

NCT01588743

Type 2 Diabetes Mellitus

UNKNOWN NA

Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes

NCT03509324

Diabetes Mellitus, Type 2

COMPLETED PHASE4

Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus

NCT00655603

Type 2 Diabetes Mellitus

UNKNOWN NA

Effects of Short-term Intensive Insulin Therapy on Long-term Complications in Type 2 Diabetes

NCT03909555

Type 2 Diabetes Mellitus

UNKNOWN

Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes

NCT02669524

Type 2 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

wDM

Early diabetes

No interventions assigned to this group

pDM

Poorly controlled diabetic patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* type 2 diabetic patients with disease duration of less than 15years
* age of 20-70 years
* BMI 22-27
* HbA1c 9-13%
* patients willing to receive intensive glucose control
* patients who are able to monitor their glucose level at home

* for normal glucose tolerance group : NGT subjects with same range of age and BMI
* for early diabetes group : patients with diabetic duration of less than 5 years and HbA1c level less than 7.5% for at least last 6 months

Exclusion Criteria

* previous history of insulin treatment
* patients taking alpha-glucosidase inhibitor or thiazolidinedione
* serum creatinine \>= 1.5 mg/dL
* hemoglobin \< 10 g/dL
* AST/ALT greater than 3 times normal range
* ischemic heart disease, congestive heart failure (NYHA grade \>=2)
* chronic renal failure, proliferative diabetic retinopathy, CVA
* patients with gastroparesis or taking medications altering gastric motility
* usage of steroid or other agents affecting glucose metabolism
* pregnant or breast-feeding women

Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes